Cover Image
市場調查報告書

Rivaroxaban的中國市場

Investigation Report on China Rivaroxaban Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 332303
出版日期 內容資訊 英文 20 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Rivaroxaban的中國市場 Investigation Report on China Rivaroxaban Market, 2010-2019
出版日期: 2015年06月04日 內容資訊: 英文 20 Pages
簡介

Rivaroxaban,由Bayer及Johnson & Johnson所開發的第一個直接凝血因子Xa抑制劑。Rivaroxaban以Xarelto為商標名在2008年10月通過加拿大及歐洲、2011年7月通過FDA認証,目前已有100個以上國家核可認証。根據Bayer和Johnson & Johnson的統計,Rivaroxaban的全球市場銷售量在2013年達到21億2400萬美元。此外中國市場自2009年推出以來銷售量便迅速擴大,2010年寫下2000萬人民幣的銷售量記錄,到2014年更成長到1億4000萬人民幣。

本報告提供中國的Rivaroxaban市場規模與今後預測,提供您主要製藥公司及劑型別市場佔有率,銷售價格等資訊。

第1章 Rivaroxaban的相關概念

  • 適應
  • 全球市場的銷售情形

第2章 中國Rivaroxaban的市場簡介

  • Rivaroxaban的專利及核準情況
  • 主要製藥公司
  • 市場規模

第3章 中國Rivaroxaban銷售情形調查

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售數

第4章 中國Rivaroxaban的主要製藥公司市場佔有率調查

  • 以銷售額為準的市場佔有率
  • 以銷售量為準的市場佔有率

第5章 中國Rivaroxaban的劑型的相關調查

  • 劑型別市場佔有率:以銷售額為準
  • 劑型別市場佔有率:以銷售量為準

第6章 中國醫院的Rivaroxaban的標準價格

第7章 中國市場中Rivaroxaban的主要製藥公司

  • Bayer HealthCare
  • Bayer AG (德國)

第8章 中國Rivaroxaban的市場預測

  • 市場規模的預測
  • 競爭情形的預測
目錄
Product Code: 1506196

Venous Thrombus Embolism (VTE), the general term for deep vein thrombosis (DVT) and pulmonary embolism (PE), poses a grave threat to those patients who have accepted Total Hip Replacement (THR) or Total Knee Replacement (TKR). It is estimated that blood clots form in 50% of THR patients and 60% of TKR patients.

According to some experts, rivaroxaban and dabigatran are the most promising antithrombotic agents which will add a new milestone to the development of cardiovascular drugs. Rivaroxaban is the first available orally active direct factor Xa inhibitor developed by Bayer/ Johnson & Johnson. In Oct. 2008, rivaroxaban was approved to come into the Canada and the EU markete under the trade name of Xarelto while on Jul. 1, 2011, it was approved by FDA to enter the American market. Rivaroxaban has been approved by more than 100 countries in the world and succeeded in entering over 75 countries. According to the statistics of Bayer/ Johnson & Johnson, the sales value of rivaroxaban in the world exceeded USD 2.124 billion in 2013, increasing by 219% compared with last year.

After rivaroxaban entering the Chinese market under the trade name of Xarelto in the latter half of 2009, it develops fast with annual sales rising from less than CNY 20 million in 2010 to CNY 140 million in 2014 and CAGR reaching up to over 70% during the period of 2010-2014. Currently, the rivaroxaban market in China has been monopolized by Bayer. The price of rivaroxaban is relatively high for it is imported. The price range of 10 mg rivaroxaban (tablets, 5 tab. per package) is 364.20-388.68 CNY/package in sample hospitals with cities differing slightly in its price. Some Chinese enterprises have been developing the generic drugs of rivaroxaban. And it is estimated that the market size of rivaroxaban in China will keep expanding in the next few years.

Readers can get at least the following information through this report:

  • market share of manufacturers of rivaroxaban in Chinese hospitals
  • price of rivaroxaban in Chinese hospitals
  • major manufacturers of rivaroxaban
  • share of different dosage forms of rivaroxaban in Chinese hospitals
  • market outlook of rivaroxaban in China

The author suggests the following groups of people purchase this report:

  • manufacturers of antithrombotic agents
  • investors/ research institutions interested in Chinese medicine market
  • any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Rivaroxaban

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Rivaroxaban in China

  • 2.1. Patent and Approval Status of Rivaroxaban in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Rivaroxaban in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Rivaroxaban in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Rivaroxaban in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Rivaroxaban in Chinese Hospitals in 2014

7. Major Manufacturers of Rivaroxaban in Chinese Market, 2010-2014

  • 7.1. Bayer HealthCare
  • 7.2. Bayer AG (Germany)

8. Market Outlook of Rivaroxaban in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landsacpe

Selected Charts

  • Chart Patent Status of Rivaroxaban in China
  • Chart Approval Information of Rivaroxaban in China
  • Chart Sales Status of Rivaroxaban in Chinese Market, 2010-2014
  • Chart Sales Value of Rivaroxaban in China, 2010-2014
  • Chart Sales Value of Rivaroxaban in Some Regions in China, 2010-2014
  • Chart Sales Value and Market Share of Rivaroxaban Made by Bayer (Germany) in China, 2010-2014
  • Chart Sales Value and Market Share of Rivaroxaban Made by Beijign Bayer in China, 2010-2014
  • Chart Price of Rivaroxaban Made by Bayer (Germany) in Some Chinese Cities in 2014
Back to Top